Cargando…
Are circulating endothelial cells the next target for transcriptome-level pathway analysis in ARDS?
Acute respiratory distress syndrome (ARDS) has had no mortality-improving pharmacological intervention despite 50 years of high-caliber research due to its heterogeneity (Huppert LA, Matthay MA, Ware LB. Semin Respir Crit Care Med 40: 31–39, 2019). For the field to advance, better definitions for AR...
Autores principales: | Costa Monteiro, Ana C., Matthay, Michael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Physiological Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110698/ https://www.ncbi.nlm.nih.gov/pubmed/36749906 http://dx.doi.org/10.1152/ajplung.00353.2022 |
Ejemplares similares
-
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS
por: Hendrickson, Carolyn M., et al.
Publicado: (2018) -
ARDS: hidden perils of an overburdened diagnosis
por: Tobin, Martin J.
Publicado: (2022) -
Redefining ARDS: a paradigm shift
por: Villar, Jesús, et al.
Publicado: (2023) -
Potential value of circulating endothelial cells for the diagnosis and treatment of COVID-19
por: Zhang, Xuchang, et al.
Publicado: (2021) -
Circulating microparticle levels are reduced in patients with ARDS
por: Shaver, Ciara M., et al.
Publicado: (2017)